BioXcel Therapeutics, Inc. (BTAI)
NASDAQ·Healthcare·Biotechnology
$1.06
-2.75%
Mkt Cap $29.51M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 26, 2026 | $151.52K | $256.00K | +68.95% | -$0.34 | -$0.58 | -70.59% | — | — |
| Q4 2025 Nov 12, 2025 | $169.02K | $98.00K | -42.02% | -$1.54 | -$2.18 | -41.56% | — | — |
| Q3 2025 Aug 12, 2025 | $257.50K | $120.00K | -53.40% | -$2.30 | -$2.45 | -6.52% | — | — |
| Q2 2025 May 12, 2025 | $350.00K | $168.00K | -52.00% | -$2.72 | -$1.50 | +44.85% | — | — |
| Q1 2025 Mar 27, 2025 | $718.26K | $366.00K | -49.04% | -$4.36 | -$3.57 | +18.12% | — | — |
| Q4 2024 Nov 14, 2024 | $1.24M | $214.00K | -82.77% | -$8.00 | -$5.12 | +36.00% | — | — |
| Q3 2024 Aug 6, 2024 | $930.00K | $1.10M | +18.71% | -$12.16 | -$3.36 | +72.37% | — | — |
| Q2 2024 May 9, 2024 | $450.00K | $582.00K | +29.33% | -$10.88 | -$13.92 | -27.94% | — | — |
| Q1 2024 Mar 12, 2024 | $710.00K | $376.00K | -47.04% | -$15.68 | -$12.16 | +22.45% | — | — |
| Q4 2023 Nov 14, 2023 | $730.00K | $341.00K | -53.29% | -$20.64 | -$27.52 | -33.33% | — | — |
| Q3 2023 Aug 14, 2023 | $450.00K | $457.00K | +1.56% | -$27.52 | -$29.28 | -6.40% | — | — |
| Q2 2023 May 8, 2023 | $500.00K | $206.00K | -58.80% | -$24.96 | -$29.44 | -17.95% | — | — |
| Q1 2023 Mar 9, 2023 | $1.25M | $238.00K | -80.96% | -$23.84 | -$31.20 | -30.87% | — | — |
| Q4 2022 Nov 10, 2022 | $1.00M | $137.00K | -86.37% | -$21.44 | -$23.84 | -11.19% | — | — |
| Q3 2022 Aug 9, 2022 | — | — | — | -$19.20 | -$21.60 | -12.50% | — | — |
| Q2 2022 May 9, 2022 | $125.00K | — | — | -$19.36 | -$17.92 | +7.44% | — | — |
| Q1 2022 Mar 10, 2022 | — | — | — | -$18.88 | -$14.88 | +21.19% | — | — |
| Q4 2021 Nov 10, 2021 | — | — | — | -$17.28 | -$15.36 | +11.11% | — | — |
| Q3 2021 Aug 10, 2021 | — | — | — | -$16.48 | -$17.76 | -7.77% | — | — |
| Q2 2021 May 10, 2021 | $9.90K | — | — | -$14.24 | -$17.28 | -21.35% | — | — |